Novartis Applauds Medicare Rx Pilot; Overall Bill “Somewhat Negative”
Executive Summary
Novartis hopes to see some immediate benefit from the Medicare prescription drug law from a Centers for Medicare & Medicaid Services pilot program to study expanded coverage of oral chemotherapy drugs
You may also be interested in...
Novartis To Consider “Off Shoring” Some Corporate Functions To India
Novartis will consider "off shoring" certain corporate functions to India
Novartis To Consider “Off Shoring” Some Corporate Functions To India
Novartis will consider "off shoring" certain corporate functions to India
J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call